The main purpose of the NOPSAD collection is to aggregate standardised jurisdictional data on the number of clients accessing pharmacotherapy for the treatment of opioid dependence, the number of prescribers participating in the delivery of pharmacotherapy treatment, and quantitative information about the prescribing sector. From this, national information on pharmacotherapy can be reported.

Collection details

Temporal coverage

from 30 June 2004 to 30 June 2017

Geographical coverage

National and state and territory 

Data availability

  • publications
  • summary tables published in electronic form
  • statistics
  • client specified tables on request which may be subject to data provider approval (charges apply)
  • unit records are not available

Data scope

Collection covers the provision of opioid pharmacotherapy treatment, the practitioners who prescribe the treatment, the dosing sites who dispense the pharmacotherapy drugs, and the clients receiving the opioid pharmacotherapy treatment. 

These pharmacotherapies are currently recommended for the treatment of opioid dependency:

  • Methadone hydrochlorideMethadone Syrup®;
  • Biodone Forte®
  • BuprenorphineSubutex®  
  • Buprenorphine/NaloxoneSuboxone®.


Admin data

Metadata information and data quality statement (DQS)

External links and information

Opioid Pharmacotherapy Statistics Annual Data collection, 2016; quality statement

Alcohol and other drug treatment services in Australia 2006–07: report on the NMDS

Data items and definitions 2008 NOPSAD data guide

2007 NOPSAD data guide

NOPSAD 2007 report

NOPSAD 2008 report

NOPSAD 2009 report

NOPSAD 2010 report

NOPSAD 2012 report

NOPSAD 2013 report

NOPSAD 2014 report

NOPSAD 2015 report

NOPSAD 2016 report


[email protected]